The University of Alberta Clinical Trials Office is the secretariat for University of Alberta Clinical Trials (UACT) and a leader in clinical trials, committed to improving health outcomes through collaboration, innovation, and intentional and meaningful inclusion of historically, and currently excluded populations. Our office supports a diverse range of clinical trials with a focus on reliability, adaptability, efficiency, accountability, and innovation.
Join the community of researchers to keep up to date with the latest news, events, announcements and developments in clincal research.
Until April 1, 2026, ICH GCP E6(R2) remains the required and accepted standard for all Health Canada–regulated trials.
Study teams are not required to take both the R2 and R3 courses during this period.
After April 1, 2026, if your R2 certification is still valid, completion of the N2 Comparison Session and Self-Attestation Form demonstrates awareness of the transition and will meet R3 training expectations.
The CTO recognizes and accepts either (a) valid E6(R2) certification with self-attestation and review of the N2 R2 to R3 comparison session, or (b) completion of E6(R3) training.
Although not required if the Self-Attestation Form is signed, the R3 certification is available to anyone who wishes to update to R3.
Please be aware, some Industry sponsors may not accept our Institutional position and will require you to take the new N2 CITI E6(R3) course after April 1, 2026.
Your Requirement:
You are not required to take the new E6(R3) course until your current certification expires.
Action Plan:
▶️ 1. Watch the N2 "E6(R2) to E6(R3) Comparison Session" recording
🖊️ 2. Sign the N2 GCP E6(R3) Self-Attestation Form.
📂 3. Keep a copy of the signed form in your training file.
Your Requirement:
Training on the new E6(R3) guidelines is now available through N2 CITI Canada.
Action Plan:
📚1. Recertify under E6(R3) via N2 CITI Canada
📂 2. Keep a copy of the updated certificate in your training file.
A 12-week program at the U of A is helping patients with chronic health issues. Watch Dr. Puneeta Tandon, the CTO Clinical Innovation Lead for Digital Health & Translational Solutions, explain the importance of breath work within the EMPOWER trial.
"Kids with broken or sprained limbs don’t need oral opioids to treat their pain, according to newly published findings from a cross-Canada study by pediatric emergency researchers."
Learn more about the work Dr. Samina Ali and her team have been doing to study treatments for pediatric musculoskeletal pain in emergency department across Canada.
Learn about new advances in wearable tech and its applications in lung health from Dr. Giovani Ferrara, the academic lead of the CTO Digital Health Unit.
Dr. Ferrara joins the Unsung Lung Podcast and discusses using AI to predict lung health flare-ups, digital health and its real life applications, and how individual statistics can have population-wide impacts.
The Women & Children's Health Research Institute (WCHRI) hosts regular learning sessions on health research topics. For a full list of upcoming sessions, and recordings of past sessions, visit the events section of WCHR website.
Join WCHRI’s academic lead for Indigenous children's health research, Grant Bruno, for a strength-based Elders’ panel focused on honouring the experiences of residential school survivors and fostering awareness through intergenerational dialogue. Rather than centering trauma, the event will highlight resilience, strength and visions for healing in child health through the voices of Elders.
Date: September 29
Time: 3–4:50 p.m.
Location: ECHA L1-490
Missed the event, or want to review what you learned? Visit WCHRI's YouTube Channel to learn more.
Health inequities among Indigenous Peoples in Canada arise from systemic injustices and require culturally responsive, community-led solutions. The Indigenous Clinical Trials Unit, the first of its kind in Canada, enables and uplifts Indigenous-designed and implemented clinical trial research that addresses the unique needs of Indigenous Peoples and communities while strengthening and promoting sovereignty and self-determination in health research innovation. The ICTU marks a significant step toward rectifying colonial impacts on health and empowering Indigenous sovereignty in healthcare.
Clinical research has immense potential to improve health outcomes for everyone. However, the historical and ongoing legacy of inequities has left
many populations excluded, including Indigenous, racialized,
2SLGBTQIA+ communities, people with disabilities, and others. The Clinical Trials Office (CTO) is committed to identifying and rectifying these inequities and ensuring clinical trials serve all communities with fairness, dignity, and respect.
Our digital Health Unit harnesses the power of cutting-edge technology and clinical research to create innovative solutions that improve health outcomes and expand access to care and clinical trials. We are at the forefront of exploring how digital tools, such as mobile apps, wearable devices and telemedicine, transform the way clinical trials are conducted and how patients engage with tier care.
We actively collaborate with academic researchers, healthcare innovators, and patients to build strong dynamic partnerships that fuel progress and innovation. From project conception through to data analysis, the Digital Health Unit provides comprehensive support every step of the way.
The University of Alberta, its buildings, labs, and research stations are primarily located on the traditional territory of Cree, Blackfoot, Métis, Nakota Sioux, Iroquois, Dene, and Ojibway/Saulteaux/Anishinaabe nations; lands that are now known as part of Treaties 6, 7, and 8 and homeland of the Métis. The University of Alberta respects the sovereignty, lands, histories, languages, knowledge systems, and cultures of First Nations, Métis and Inuit nations.